{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04651855",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ALSTEM"
      },
      "Organization": {
        "OrgFullName": "Polski Bank Komorek Macierzystych JSC (PBKM)",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS",
      "OfficialTitle": "The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "Acronym": "ALSTEM"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 30, 2020",
      "StudyFirstSubmitQCDate": "December 2, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 3, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 2, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 3, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Polski Bank Komorek Macierzystych JSC (PBKM)",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Center for Research and Development, Poland",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The objective of this study is to evaluate the safety of intrathecal administration of Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of patients with Amyotrophic Lateral Sclerosis.",
      "DetailedDescription": "Clinical Phase: I/II\n\nPopulation: Patients with Amyotrophic Lateral Sclerosis.\n\nProject Design: One arm, non-blinded, open label study\n\nPlanned Sample Size: 20 patients\n\nInvestigational Medicinal Product: active IMP - mesenchymal stem cells isolated from Wharton's jelly\n\nScreening:\n\nThree visits on site to check the eligibility criteria (around 90, 60 and 30 days before first IMP administration)\n\nTreatment (IMP administration):\n\nEach patient will receive IMP three times: on baseline (day 0), 30 and 60 days after baseline (+/- 7 days).\n\nAdministration route: intrathecal\n\nFollow up:\n\nDuration: 18 months after first IMP administration Four on-site visits (3, 6, 9, 12 months after first IMP administration) and seven phone visits (4, 5, 7, 8, 10, 11 and 18 months after first IMP administration)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Amyotrophic Lateral Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Amyotrophic Lateral Sclerosis",
          "Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment arm",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal stem cells isolated from Wharton's jelly"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal stem cells isolated from Wharton's jelly",
            "InterventionDescription": "Intrathecal administration of mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment arm"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The number of (S)AESI [(Serious) Adverse Event of Special Interest]",
            "PrimaryOutcomeDescription": "(S)AESI are defined as:\n\nMeningitis and encephalitis.\nToxic encephalopathy.\nHigh fever >39‚Å∞C.\nEpileptic seizures that are not connected to conditions above (meningitis, encephalitis, toxic encephalopathy, high fever).",
            "PrimaryOutcomeTimeFrame": "3 month FU (follow-up)"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Disease progression",
            "SecondaryOutcomeDescription": "Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 48 points",
            "SecondaryOutcomeTimeFrame": "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Pulmonary function decline",
            "SecondaryOutcomeDescription": "Pulmonary function decline assessed in spirometry (forced vital capacity)",
            "SecondaryOutcomeTimeFrame": "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU."
          },
          {
            "SecondaryOutcomeMeasure": "Muscle strength decline",
            "SecondaryOutcomeDescription": "Muscle strength decline assessed in physical examination",
            "SecondaryOutcomeTimeFrame": "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Upper motor neuron function",
            "SecondaryOutcomeDescription": "Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points",
            "SecondaryOutcomeTimeFrame": "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Cognitive function",
            "SecondaryOutcomeDescription": "Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 136 points",
            "SecondaryOutcomeTimeFrame": "screening and 12 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Quality of life changes",
            "SecondaryOutcomeDescription": "Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.",
            "SecondaryOutcomeTimeFrame": "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)",
            "SecondaryOutcomeDescription": "The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH level assessed in the samples of CSF",
            "SecondaryOutcomeTimeFrame": "run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)"
          },
          {
            "SecondaryOutcomeMeasure": "The change of defined cytokines, chemokines and cystatin C level in blood",
            "SecondaryOutcomeDescription": "The change of defined cytokines, chemokines and cystatin C level assessed in the samples of blood serum",
            "SecondaryOutcomeTimeFrame": "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU."
          },
          {
            "SecondaryOutcomeMeasure": "The change of creatinine and p75ECD level in urine",
            "SecondaryOutcomeDescription": "The change of creatinine and p75ECD level",
            "SecondaryOutcomeTimeFrame": "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU."
          },
          {
            "SecondaryOutcomeMeasure": "Muscle function changes",
            "SecondaryOutcomeDescription": "Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)",
            "SecondaryOutcomeTimeFrame": "baseline and at 1, 2, 6 and 12 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "The change of the brain visualization",
            "SecondaryOutcomeDescription": "The change of the brain visualization in MRI (T1, T2 and DTI)",
            "SecondaryOutcomeTimeFrame": "run-in visit (-60 day), 6 and 12 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI",
            "SecondaryOutcomeDescription": "The number of SAE/AE and (S)AESI - defined as in Outcome 1",
            "SecondaryOutcomeTimeFrame": "18 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Survival period to disease progression",
            "SecondaryOutcomeDescription": "The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:\n\nPAV (permanent assisted ventilation)\nTracheostomy\nDeath",
            "SecondaryOutcomeTimeFrame": "18 month FU"
          },
          {
            "SecondaryOutcomeMeasure": "Mortality rate",
            "SecondaryOutcomeDescription": "Percentage of deaths in the entire study population.",
            "SecondaryOutcomeTimeFrame": "18 month FU"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAdult patients (at least 18 years old)\nThe minimum patient's weight is not less than 40 kg\nDiagnosis of sporadic ALS, definite or probable, as defined by El Escorial World Federation of Neurology criteria\nHistory of ALS symptoms less than 2 years duration from the first symptoms of the disease\nMore than 6 months from diagnosis of the disease\nDisease progression at 6 past months at least 3 points during this period of time\nALSFRS-R scale of at least 30 at screening appointment\nForced vital capacity >70% of predicted value for age, gender and height\nTreatment with stable dose of riluzole before baseline visit (for at least 1 month)\nCapable of providing written informed consent\nAble to comply with study requirements and willing to follow all study procedures and follow-up visits\nWomen of child-bearing age and men with partners of child-bearing potential must agree to use two forms of contraceptive therapy throughout the course of the trial\nWomen of child-bearing age must undergo pregnancy test\nPolish-language native speakers or patients who are proficient in the Polish language\n\nExclusion Criteria:\n\nPregnancy or breastfeeding\nTracheostomy\nVentilator dependence\nRenal disease with creatinine >2mg/dl\nLiver disease with ALT, AST or GGTP 2-fold higher than upper normal limit\nPositive test for HBV, HCV, HIV with NAT method\nPositive tests for syphilis\nAny other clinically significant abnormalities on laboratory evaluation\nAny condition that would compromise ability of undergoing lumbar puncture\nActive systemic disease\nAutoimmune disease (Hashimoto disease under control is allowed)\nUncontrolled diabetes\nPulmonary disease that could affect interpretation of spirometry\nNeurological concomitant disease\nUnstable psychiatric concomitant disease\nHigh risk of suicide\nHistory of substance abuse within past year\nHistory of malignancy, within the previous 5 years, including melanoma with exception of localized skin cancers\nAny other clinically significant medical condition that can compromise patient's safety in the opinion of the investigator\nTreatment with immunomodulatory drugs (for example immunoglobulins, corticosteroids or other immunosuppressant) in last 6 months\nParticipation in another clinical trial in last 6 months\nPrevious cellular therapy of any kind\nHypersensitivity to any component used in the cell culture\nNuchal rigidity and other signs of meningitis\nPatients on chronic anticoagulation treatment (heparin/ warfarin/acenocoumarol/(N)OAC)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Natalia ≈ªmijewska",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "0048-22-436-40-50",
            "CentralContactEMail": "Natalia.Zmijewska@pbkm.pl"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "JST sp. z o.o.",
            "LocationStatus": "Recruiting",
            "LocationCity": "Czƒôstochowa",
            "LocationZip": "42-202",
            "LocationCountry": "Poland",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Beata ≈öwiƒÖtkowska-Flis, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "beatasflis@gmail.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000016472",
            "ConditionMeshTerm": "Motor Neuron Disease"
          },
          {
            "ConditionMeshId": "D000000690",
            "ConditionMeshTerm": "Amyotrophic Lateral Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009468",
            "ConditionAncestorTerm": "Neuromuscular Diseases"
          },
          {
            "ConditionAncestorId": "D000013118",
            "ConditionAncestorTerm": "Spinal Cord Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000057177",
            "ConditionAncestorTerm": "TDP-43 Proteinopathies"
          },
          {
            "ConditionAncestorId": "D000057165",
            "ConditionAncestorTerm": "Proteostasis Deficiencies"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M18031",
            "ConditionBrowseLeafName": "Motor Neuron Disease",
            "ConditionBrowseLeafAsFound": "Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3176",
            "ConditionBrowseLeafName": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafAsFound": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11563",
            "ConditionBrowseLeafName": "Neuromuscular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15067",
            "ConditionBrowseLeafName": "Spinal Cord Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27912",
            "ConditionBrowseLeafName": "TDP-43 Proteinopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27900",
            "ConditionBrowseLeafName": "Proteostasis Deficiencies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4699",
            "ConditionBrowseLeafName": "Primary Lateral Sclerosis",
            "ConditionBrowseLeafAsFound": "Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T349",
            "ConditionBrowseLeafName": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafAsFound": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}